Forecyte Bio opened its brand-new, state-of-the-art cell and gene therapy GMP facility in Shanghai, China, on March 31, following the opening of its U.S. facility in January.

The 140,000 square foot facility, with a price tag of nearly $40 million, offers multiple GMP production lines for plasmids, viral vectors, and cell therapies. The dual sites in the U.S. and China offer advantages to cell and gene therapy (CGT) companies, especially those with the intention of filing internationally.

According to the company, both facilities offer high-quality production capacities operated by industry veterans and an executive team experienced in CGT CMC manufacturing. Forecyte Bio’s 4×4 holistic approach covers a wide range of the CGT CMC workflow.

Through its high-quality, efficient and agile services, Forecyte Bio helps its customers to accelerate their product development process from R&D to clinic and to the market, and at the same time enables cell and gene therapy products to be manufactured and filed in multiple nations.

“The CGT industry has entered a stage of rapid development. Forecyte Bio adheres to the standard of serving customers with quality, efficiency and agility, and strives to accelerate patients’ access to the advanced cell and gene therapy,” said Yingke He, founder and CEO of Forecyte Bio. “With the opening of the Shanghai production and R&D center, the manufacturing capacity of Forecyte Bio in China and the United States are ready to serve its customers from US, China and around the globe. Thanks to the trust and support from our landlord, our customers and investors, and mostly our hardworking employees, we have been able to reach today’s achievement in such a short time.”